FDA approved Eli Lilly & Co./Boehringer Ingelheim GMBH’s copycat version of Sanofi’s Lantus (insulin glargine) Dec. 16, paving the way for a launch as anticipated in December 2016. FDA approved the long-acting insulin, Basaglar (insulin glargine), in adult and pediatric patients with type 1 and type 2 diabetes.
The approval follows the tentative approval granted for Lilly/BI’s NDA for Basaglar in August 2014 ([A#14140819002]). The tentative approval...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?